Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 1B, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND PRELIMINARY EFFICACY OF CEMSIDOMIDE IN COMBINATION WITH ELRANATAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA SUBJECTS

Next Previous
Trial Profile

A PHASE 1B, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND PRELIMINARY EFFICACY OF CEMSIDOMIDE IN COMBINATION WITH ELRANATAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA SUBJECTS

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemsidomide (Primary) ; Dexamethasone (Primary) ; Elranatamab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors C4 Therapeutics

Most Recent Events

  • 11 Aug 2026 According to C4 Therapeutics media release, the company expects to provide an update on the dose escalation progress in the second half of 2026 with data from all cohorts expected in mid-2027.
  • 12 May 2026 According to C4 Therapeutics media release, the company will provide an update on the dose escalation progress from the Phase 1b trial evaluating the combination of cemsidomide, dexamethasone, and elranatamab in 2H 2026.
  • 25 Mar 2026 According to C4 Therapeutics media release, first patient has been dosed with cemsidomide in this study. Data from all cohorts (75, 50 and 100 µg doses) evaluating cemsidomide in combination with elranatamab is anticipated in mid-2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top